Insight Molecular Diagnostics
IMDX
41 hedge funds and large institutions have $62.1M invested in Insight Molecular Diagnostics in 2026 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 7 closing their positions.
143% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 7
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
17% more funds holding
Funds holding: 35 → 41 (+6)
0.78% more ownership
Funds ownership: 58.09% → 58.87% (+0.78%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
50% less capital invested
Capital invested by funds: $125M → $62.1M (-$62.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$4.88M |
| 2 |
BC
Broadwood Capital
New York
|
+$3.03M |
| 3 |
HCM
Heights Capital Management
San Francisco,
California
|
+$2.28M |
| 4 |
FIA
FNY Investment Advisers
New York
|
+$1.2M |
| 5 |
FOR
Family Office Research
Bethesda,
Maryland
|
+$739K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$319K |
| 2 |
6CM
683 Capital Management
New York
|
-$280K |
| 3 |
Goldman Sachs
New York
|
-$180K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$117K |
| 5 |
Renaissance Technologies
New York
|
-$101K |
IMDX Hedge Fund Activity: Q1 2026 in Review
41 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q1 2026, worth a combined $62.1M — down 50% from $125M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new IMDX positions and 7 closed out — a net gain of 10 holders — while 11 added to existing stakes and 6 trimmed.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $4.88M. The largest seller was Jane Street, exiting entirely with an estimated $319K sold.
- 41 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q1 2026, up from 35 in Q4 2025.
- Funds reported $62.1M of Insight Molecular Diagnostics stock for Q1 2026, down 50% quarter-over-quarter.
- 17 funds opened new Insight Molecular Diagnostics positions in Q1 2026 and 7 closed out, a net change of +10 holders.
- The largest Insight Molecular Diagnostics buyer in Q1 2026 was Alyeska Investment Group, an estimated $4.88M added.
- The largest Insight Molecular Diagnostics seller in Q1 2026 was Jane Street, an estimated $319K sold.
Based on aggregated 13F filings for Q1 2026.